All News

RheumNow Podcast square

Night Splinting for Carpal Tunnel (3.24.2023)

d Jack Cush, MD
Mar 24, 2023

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Read Article
Dr. Eric Ruderman with an excellent review of the JAK/STAT pathway especially for PsA treatment @RheumNow #RNL2023 https://t.co/kNDouZ4kCV
Robert B Chao, MD doctorRBC ( View Tweet)
Mar 19, 2023
TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Safer? No lab monitoring And it works https://t.co/9Woen2q4hZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Mar 19, 2023
TYK2 signalling Vs JAK signalling summary #RNL2023 https://t.co/0VNBiEc6jq
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Mar 19, 2023
Why JAKinibs in PsA ?! By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Also inflammatory bowel disease and most recently Upadacitinib for crohns disease. https://t.co/loUgJNUsKT
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Mar 18, 2023
Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Good news, especially with Updacitinib recently and Crohn’s disease ( full package). https://t.co/nlBWJhzpLp
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Mar 18, 2023
@RheumNow Live #RNL2023 Stanley Cohen, MD: Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16 ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG
Eric Dein ericdeinmd ( View Tweet)
Mar 18, 2023
JAKinib safety takeaways - avoid in older population > 65 yo, malignancy, CV risk, VTE risk - appropriate in younger pts without VTE/CVD risk factors #RNL2023 @RheumNow https://t.co/5i1bRqqr7g
Robert B Chao, MD doctorRBC ( View Tweet)
Mar 18, 2023
#RNL2023 @RheumNow Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/AZDKShOPbU
Eric Dein ericdeinmd ( View Tweet)
Mar 18, 2023
The amazing JAKs The many JAK/TYK targets approved for multiple conditions Coming soon: UPA for Crohn's - first indication for Crohn's disease #RNL2023 @RheumNow https://t.co/Pf3gzrdyeq
Eric Dein ericdeinmd ( View Tweet)
Mar 18, 2023
Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/3ZZHr0akrR
Robert B Chao, MD doctorRBC ( View Tweet)
Mar 18, 2023
JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 ⁦@RheumNow⁩ https://t.co/qBau79o0VQ
Dr. Rachel Tate uptoTate ( View Tweet)
Mar 18, 2023
ARTIS Swedish study of Cancer in RA or PSA pts (~15k pts) starting JAKi vs TNFi. With ~2 yrs F/U, the risk of Cancer (excluding NMSC) was similar betw JAKi and TNFi (HR 0.94; 0.65 to 1.38), but more incident NMSC w/ JAKi (HR 2.12; 1.15 to 3.89) at 2 yrs https://t.co/BiPWF1T0lZ https://t.co/nrmaCGBcce

Links:

Dr. John Cush RheumNow ( View Tweet)
Mar 07, 2023
RheumNow Podcast square

NSAIDs in Pregnancy (3.3.2023)

d Jack Cush, MD
Mar 03, 2023

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Read Article
CorEvitas registry data shows H2H comparison of 369 CCP+ abatacept & 475 CCP+ tofacitinib treated patients showed equivalent drug responses (reduced CDAI or PRO's); b/tsDMARD naive pts had numerically better ABA response at 6 mos (P = 0.662) https://t.co/36jr7l2DKm https://t.co/PItYrvMUNV

Links:

Dr. John Cush RheumNow ( View Tweet)
Mar 02, 2023
Lupusfoto.jpg

Phase 3 Trials of Baricitinib Disappoint in SLE

d Jack Cush, MD
Feb 27, 2023

Despite the encouraging phase II trial results of baricitinib in systemic lupus erythematosus (SLE) patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE, thereby halting development of baricitinib in SLE. 

Read Article
Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 18, 2023
computer screen safety

Drug Safety Differences with New Novel Therapies in RA

d Jack Cush, MD
Feb 14, 2023

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Read Article
Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 13, 2023
The FDA has added a new indication to the oral JAK inhibitor Cibinqo (abrocitinib) - now approved to treat atopic dermatitis in adolescents 12 to under 18 years old. (Approval is based on a phase 3 JADE TEEN trial. https://t.co/DsQj3BfPmZ https://t.co/0bpb2FAwpg

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 10, 2023

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×